Table 1.

Demographics and clinical characteristics of study participants

CharacteristicTotal (n = 28)Cont IgGRT (n = 17)No IgGRT (n = 11)P value
Sex, male, n (%) 10 (36) 5 (29) 5 (45) ns 
Age, years, median (range) 59 (32–75) 58 (32–71) 60 (43–75) ns 
Years since diagnosis, median (range) 2 (0–30) 1 (0–30) 3 (1–21) ns 
scIgGRT, n (%) 27 (96) 16 (94) 11 (100) ns 
Dose IgGRT, mg/kg/wk, median (range) 103 (50–174) 101 (92–174) 103 (50–120) ns 
Ever vaccinateda, n (%) 13 (46) 8 (41) 5 (45) ns 
Infections with IgGRT, median (range) 2 (0–13) 2 (0–8) 2 (0–13) ns 
Infections without IgGRT, median (range) 3 (0–7) 3 (0–7) 2 (0–6) ns 
Months without IgGRT, median (range) 18 (6–19) 17 (6–18) 18 (18–19) – 
Chronic lung diseaseb, n (%) 12 (43) 7 (41) 5 (45) ns 
Bronchiectasis, n (%) 8 (29) 4 (24) 4 (36) ns 
Lung function %c, median (range) 91 (40–114) 90 (40–114) 91 (50–107) ns 
Autoimmunity, n (%) 15 (54) 10 (59) 5 (45) ns 
Systemic corticosteroidsd 6 (21) 1 (6.0) 5 (45) 0.022 
Immune suppression – 
Subnormal total IgG, n (%) 15 (54) 11 (65) 4 (36) ns 
Subnormal IgA, n (%) 6 (21) 5 (29) 1 (9.0) ns 
Subnormal IgG1 5 (18) 5 (29) ns 
Subnormal IgG2 11 (39) 9 (50) 2 (18) ns 
Subnormal IgG3 18 (64) 11 (65) 7 (64) ns 
Complexe IgGSD, n (%) 9 (33) 8 (47) 1 (9.0) 0.047 
MBL deficiency, n (%) 6 (21) 3 (18) 3 (27) ns 
IgM, g/L, median (range) 0.82 (0.07–3.0) 0.81 (0.07–2.3) 0.84 (0.3–3.0) 0.27–2.1 
IgG, g/L, median (range) 6.2 (2.1–12) 5.4 (2.2–11.9) 8.2 (4.9–11.3) 6.7–15 
IgA, g/L, median (range) 1.5 (0.09–3.8) 1.5 (0.09–2.8) 1.7 (0.84–3.8) 0.88–4.5 
IgG1, g/L, median (range) 3.8 (1.4–10) 3.6 (1.4–10.3) 4.1 (3.3–9.0) 2.8–8.0 
IgG2, g/L, median (range) 1.6 (0–4.5) 1.0 (0–4.5) 2.4 (0.55–4.2) 1.15–5.7 
IgG3, g/L, median (range) 0.16 (0–1.0) 0.12 (0–0.9) 0.2 (0–0.5) 0.24–1.3 
CharacteristicTotal (n = 28)Cont IgGRT (n = 17)No IgGRT (n = 11)P value
Sex, male, n (%) 10 (36) 5 (29) 5 (45) ns 
Age, years, median (range) 59 (32–75) 58 (32–71) 60 (43–75) ns 
Years since diagnosis, median (range) 2 (0–30) 1 (0–30) 3 (1–21) ns 
scIgGRT, n (%) 27 (96) 16 (94) 11 (100) ns 
Dose IgGRT, mg/kg/wk, median (range) 103 (50–174) 101 (92–174) 103 (50–120) ns 
Ever vaccinateda, n (%) 13 (46) 8 (41) 5 (45) ns 
Infections with IgGRT, median (range) 2 (0–13) 2 (0–8) 2 (0–13) ns 
Infections without IgGRT, median (range) 3 (0–7) 3 (0–7) 2 (0–6) ns 
Months without IgGRT, median (range) 18 (6–19) 17 (6–18) 18 (18–19) – 
Chronic lung diseaseb, n (%) 12 (43) 7 (41) 5 (45) ns 
Bronchiectasis, n (%) 8 (29) 4 (24) 4 (36) ns 
Lung function %c, median (range) 91 (40–114) 90 (40–114) 91 (50–107) ns 
Autoimmunity, n (%) 15 (54) 10 (59) 5 (45) ns 
Systemic corticosteroidsd 6 (21) 1 (6.0) 5 (45) 0.022 
Immune suppression – 
Subnormal total IgG, n (%) 15 (54) 11 (65) 4 (36) ns 
Subnormal IgA, n (%) 6 (21) 5 (29) 1 (9.0) ns 
Subnormal IgG1 5 (18) 5 (29) ns 
Subnormal IgG2 11 (39) 9 (50) 2 (18) ns 
Subnormal IgG3 18 (64) 11 (65) 7 (64) ns 
Complexe IgGSD, n (%) 9 (33) 8 (47) 1 (9.0) 0.047 
MBL deficiency, n (%) 6 (21) 3 (18) 3 (27) ns 
IgM, g/L, median (range) 0.82 (0.07–3.0) 0.81 (0.07–2.3) 0.84 (0.3–3.0) 0.27–2.1 
IgG, g/L, median (range) 6.2 (2.1–12) 5.4 (2.2–11.9) 8.2 (4.9–11.3) 6.7–15 
IgA, g/L, median (range) 1.5 (0.09–3.8) 1.5 (0.09–2.8) 1.7 (0.84–3.8) 0.88–4.5 
IgG1, g/L, median (range) 3.8 (1.4–10) 3.6 (1.4–10.3) 4.1 (3.3–9.0) 2.8–8.0 
IgG2, g/L, median (range) 1.6 (0–4.5) 1.0 (0–4.5) 2.4 (0.55–4.2) 1.15–5.7 
IgG3, g/L, median (range) 0.16 (0–1.0) 0.12 (0–0.9) 0.2 (0–0.5) 0.24–1.3 

Cont, need for continued therapy after the study; MBL, mannose-binding lectin.

a

Pneumococcal vaccination 1–20 years prior to blood sample collection.

b

Asthma or chronic obstructive pulmonary disease.

c

FEV1%.

d

>1 prednisone taper or >5 mg daily prednisone.

e

Deficient in >1 IgG subclass.

or Create an Account

Close Modal
Close Modal